Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Amortization - Intangibles (2016 - 2025)

Historic Amortization - Intangibles for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $855000.0.

  • Harvard Bioscience's Amortization - Intangibles fell 3590.7% to $855000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 1766.02%. This contributed to the annual value of $5.3 million for FY2024, which is 488.69% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Amortization - Intangibles is $855000.0, which was down 3590.7% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Amortization - Intangibles ranged from a high of $1.6 million in Q4 2022 and a low of $855000.0 during Q3 2025
  • For the 5-year period, Harvard Bioscience's Amortization - Intangibles averaged around $1.4 million, with its median value being $1.4 million (2023).
  • In the last 5 years, Harvard Bioscience's Amortization - Intangibles soared by 1263.89% in 2022 and then crashed by 3590.7% in 2025.
  • Over the past 5 years, Harvard Bioscience's Amortization - Intangibles (Quarter) stood at $1.4 million in 2021, then grew by 12.64% to $1.6 million in 2022, then fell by 14.49% to $1.4 million in 2023, then decreased by 9.37% to $1.3 million in 2024, then tumbled by 31.98% to $855000.0 in 2025.
  • Its Amortization - Intangibles stands at $855000.0 for Q3 2025, versus $1.2 million for Q2 2025 and $1.2 million for Q1 2025.